Small-Cap Biopharma and Biosafety Innovators in the Spotlight: SXTP and NDTP on Bloomberg TV

The biopharma and biosafety sectors have long been fertile ground for innovation, but in Q3 2025, two small-cap players-60 Degrees Pharmaceuticals (NASDAQ: SXTP) and Neoleukin Therapeutics (NDTP)-have emerged as compelling candidates for undervalued growth opportunities. Both companies have drawn attention on Bloomberg TV, where analysts highlighted their potential to reshape disease prevention and treatment paradigms. This analysis explores their strategic positioning, R&D advancements, and financial trajectories, underscoring why they warrant closer scrutiny from investors seeking high-impact, niche-market exposure.

60 Degrees Pharmaceuticals (SXTP): A Biosafety Pioneer with Regulatory Tailwinds

60 Degrees Pharmaceuticals has carved a niche in addressing vector-borne and chronic infectious diseases, a sector poised for expansion as public health priorities shift toward prevention. In Q3 2025, the company in net product revenue, , ARAKODA®. , the company's biosafety initiatives have gained momentum.

A key milestone is the launch of the , a Phase 2 open-label trial evaluating tafenoquine for treating chronic babesiosis, . cases according to the announcement. This trial, conducted in partnership with Tulane University and the Icahn School of Medicine at Mount Sinai, positions 60 Degrees at the forefront of unmet medical needs. The company's focus on regulatory shifts-such as the federal ban on synthetic food dyes and state-level restrictions-further amplifies its long-term growth potential in biosafety-driven markets.

Bloomberg TV coverage has spotlighted SXTP as an undervalued play, emphasizing its dual role in pharmaceuticals and biosafety. Analysts note that the company's partnerships and pipeline diversification could unlock value as it scales its infectious disease solutions.

Neoleukin Therapeutics (NDTP): Redefining Immuno-Oncology for "Cold" Tumors

Neoleukin Therapeutics is tackling one of immuno-oncology's most persistent challenges: treating "cold" tumors that evade immune detection. The company's EVOLVE™ platform leverages multi-functional T cell engagers (TCEs) with integrated co-stimulation, a novel approach to overcoming resistance in solid tumors. Early-phase trials for EVT-201 (targeting solid tumors) and EVT-101 (for pancreatic cancer) have shown promising results, according to industry analysis.

NDTP's strategic roadmap includes a pivotal with anti-PD-1 set to begin in August 2025, a milestone that could validate its platform's efficacy in immune-resistant cancers. Bloomberg TV has highlighted NDTP as an undervalued innovator, citing its subsidiary Good Salt Life, which offers EPA-approved antimicrobial solutions and data-driven disinfection protocols across 11 countries according to Bloomberg TV coverage. This dual focus on oncology and biosafety positions NDTP to capitalize on cross-sector demand for disease prevention technologies.

Undervalued Growth: Aligning Innovation with Market Realities

Both SXTP and NDTP exemplify the "undervalued growth" narrative, with market valuations that understate their R&D pipelines and strategic partnerships. For SXTP, . Similarly, according to industry reports.

Bloomberg TV coverage has amplified these themes, with analysts noting that SXTP's ARAKODA® revenue growth and NDTP's immuno-oncology advancements align with broader trends in health prevention. The platforms' focus on niche but high-impact areas-such as babesiosis treatment and cold tumor therapies-positions them to benefit from increased R&D funding and public health investments according to Bloomberg TV analysis.

Conclusion: A Dual Opportunity in Health and Disease Prevention

The spotlight on SXTP and NDTP reflects a broader shift in investor sentiment toward small-cap biopharma innovators addressing unmet medical needs. 60 Degrees Pharmaceuticals' regulatory-driven growth and NDTP's cutting-edge immuno-oncology platform represent complementary strategies for capturing value in the biosafety and disease prevention sectors. As both companies advance their pipelines and expand partnerships, they offer a compelling case for investors seeking exposure to high-impact, underappreciated innovations.

In an era where public health challenges demand agile, science-driven solutions, SXTP and NDTP stand out as exemplars of the potential for small-cap biopharma to deliver outsized returns while advancing global health outcomes.